NCT01216267

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: University of Western Ontario, Canada · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to compare several methods for measurement of Chromogranin A in their ability to serve as a marker for disease activity in patients with neuroendocrine tumors. Further, in a subgroup, we will determine if taking a proton pump inhibitor affects Chromogranin A levels.

Detailed description

Patient group: patients with neuroendocrine tumors (active or inactive) Healthy volunteers

Conditions

• Neuroendocrine Carcinoma (Carcinoid)

Interventions

Type	Name	Description
DRUG	Lansoprazole	lansoprazole 30 mg HS x 7 days
DRUG	lansoprazole	lanzoprazole 30 mg HS for 7 days

Timeline

• Start date: 2010-06-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2010-10-07
• Last updated: 2013-01-16

Locations

1 site across 1 country: Canada